Figure 7.
MAPK15 depletion inhibits BCR-ABL1-dependent cell proliferation and transformation. (A) HeLa cells were transfected with SCR siRNA or MAPK15 specific siRNA. After 8 h cells were transfected with BCR-ABL1 or control plasmids. After further 64 h, cells were harvested and counted. (B) HeLa cells were transfected with SCR siRNA or MAPK15 specific siRNA. After 24 h cells were transfected with BCR-ABL1 or control plasmids. Cells were then assessed for anchorage-independent growth by seeding them into agar medium. After 14 d, colonies were counted. All quantitative data shown represent the means ± SD of 3 independent experiments (n = 3). (C) K562 cells, stable for the indicated shRNA-encoding plasmids, were seeded in 6-well plates at 2 × 105 cells per well in triplicate. After 72 h, cells were harvested and counted. One-way ANOVA test comparing each shSCR cell line with each shMAPK15 cell line resulted in a P value significance lower than 0.001 (***). (D) Growth curves of tumors generated by K562 cells stably expressing 2 independent shRNA SCR (#509 and #543) and 2 independent shRNA for MAPK15 (#547 and #549), after injection on the flank of athymic nude-FOXN1nu mice. Each point represents the mean volume ± SEM of 10 tumors. One-way ANOVA test for tumor volume at time points of 13, 16, 19 d comparing each shSCR xenograft group with each shMAPK15 xenograft group resulted in a P value significance lower than 0.001 (***).